Category

Press Releases
20
Sep

Coave Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

20 September 2022,
Read More
12
Sep

Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders

12 September 2022
Read More
06
Sep

Coave Therapeutics Strengthens Leadership Team with the Appointments of Catherine Mathis as Vice President Regulatory Affairs and Julien Berger as Head of Legal Affairs

6 September 2022
Read More
29
Jun

Coave Therapeutics Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Next-generation Gene Therapies Targeting CNS Diseases

29 June 2022
Read More
09
Jun

Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for process development of AAV-based gene therapy

9 June 2022
Read More
03
May

Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT

3 May 2022
Read More
27
Apr

Coave Therapeutics will be presenting an abstract at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held in Denver, Colorado 1-4 May 2022. The meeting will also be available for virtual attendees 11-12 May.

27 April 2022
Read More
13
Apr

Coave Therapeutics to Present at Cell & Gene Meeting on the Mediterranean

13 April 2022
Read More
15
Nov

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

15 November 2021
Read More
12
Oct

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board

12 October 2021
Read More
1 2
WordPress Cookie Plugin by Real Cookie Banner